India-based Veeda Group on Thursday unveiled a new logo and brand identity, Veeda Lifesciences.
The company said that the new brand name reflects its evolution from a generics-focused Contract Research Organisation (CRO) to a drug development services enterprise for different modalities of drugs including generics and novel chemical and biological entities. Veeda Lifesciences will operate through four Strategic Business Units: Clinical Trials, Healthy Volunteer Services, Biopharma Services, and Preclinical & Non-Clinical Testing Services, making Veeda an integrated research service provider.
Veeda Lifesciences integrates Veeda Clinical Research, Health Data Specialists, and Bioneeds India, showcasing research services across various stages of the drug development value chain from discovery and preclinical to late-phase development. The new identity reflects the company's transition from generics to innovation, local to global, and small molecules to biologics. Veeda Lifesciences is transitioning to a CRO-CDMO model, while leveraging AI and real-world data.
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
LPOXY Therapeutics acquires Xeno Biosciences' key assets
GSK's Nucala approved in China for chronic rhinosinusitis with nasal polyps
Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044
Neumora Therapeutics reports Navacaprant's KOASTAL-1 Study data in major depressive disorder
Veeda Group rebrands as 'Veeda Lifesciences'
Innovent and Roche agree exclusive global licence for novel DLL3 ADC